Entrada Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entrada Therapeutics, Inc. (TRDA) on June 3, 2025, reporting events occurring on May 30, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, MA.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors expanded from six to seven members.
- New Appointment: Maha Radhakrishnan, M.D., was appointed as a Class III director effective June 1, 2025, serving until the 2027 annual meeting.
- Committee Assignment: Dr. Radhakrishnan was appointed to the Audit Committee, replacing Kush Parmar, M.D., Ph.D. Dr. Parmar remains a director and Chairman of the Board.
- Independence: The Board determined Dr. Radhakrishnan is independent under Nasdaq listing standards.
Compensation and Governance Details
Dr. Radhakrishnan's compensatory arrangements include:
- Initial Stock Option: An option to purchase the lesser of shares with a value of $500,000 or 38,000 shares of Common Stock, vesting in equal monthly installments over three years.
- Cash Fees: An annual director fee of $40,000 and an annual Audit Committee fee of $9,000.
- Future Grants: Eligibility for annual stock option grants beginning in 2026, valued at the lesser of $250,000 or 19,000 shares, vesting in full upon the earlier of the first anniversary of the grant or the next Annual Meeting.
Management Commentary and Background
Dr. Radhakrishnan brings significant industry experience, having served as Executive Partner at Sofinnova Investments since August 2024. Previously, she was Group Senior Vice President and Chief Medical Officer at Biogen, Inc. (2020-2024) and held leadership roles at Sanofi, Bioverativ, Bristol Myers Squibb, and UnitedHealth Group. She has no family relationships with current directors or officers, and no related person transactions exist.
Investor Verification Checklist
- Verify the exact number of shares underlying the initial $500,000 stock option grant based on the grant date fair value.
- Confirm the updated composition of the Audit Committee and the independence status of all members.
- Review the Company's Third Amended and Restated Non-Employee Director Compensation Policy for full vesting conditions.
- Check for any subsequent filings regarding the resignation of Dr. Parmar from the Audit Committee.